Nora Therapeutics
Total Raised
$33.88MInvestors Count
5Deal Terms
2Funding, Valuation & Revenue
3 Fundings
Nora Therapeutics has raised $33.88M over 3 rounds.
Nora Therapeutics's latest funding round was a Debt for $1M on October 13, 2015.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/13/2015 | Debt | $1M | Undisclosed Investors | 1 | ||
4/17/2014 | Series B | |||||
9/23/2010 | Series A |
Date | 10/13/2015 | 4/17/2014 | 9/23/2010 |
|---|---|---|---|
Round | Debt | Series B | Series A |
Amount | $1M | ||
Investors | Undisclosed Investors | ||
Valuation | |||
Revenue | |||
Sources | 1 |
Nora Therapeutics Deal Terms
2 Deal Terms
Nora Therapeutics's deal structure is available for 2 funding rounds, including their Series B from April 17, 2014.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Nora Therapeutics Investors
5 Investors
Nora Therapeutics has 5 investors. Prospect Venture Partners invested in Nora Therapeutics's Series B funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/23/2010 | 4/17/2014 | 2 Series A, Series B (2014) | David Schnell, and Donald Hayden | Venture Capital | California | |
Venture Capital | California | |||||
Venture Capital | California | |||||
Venture Capital | New York | |||||
Holding Company | Denmark |
First funding | 9/23/2010 | ||||
|---|---|---|---|---|---|
Last Funding | 4/17/2014 | ||||
Investor | |||||
Rounds | 2 Series A, Series B (2014) | ||||
Board Seats | David Schnell, and Donald Hayden | ||||
Type | Venture Capital | Venture Capital | Venture Capital | Venture Capital | Holding Company |
Location | California | California | California | New York | Denmark |
Compare Nora Therapeutics to Competitors
Tacere Therapeutics is a biotechnology company focused on the development of novel therapeutics for serious infectious diseases. The company specializes in RNA interference (RNAi) technology to create treatments that target and silence specific genes associated with the progression of diseases such as Hepatitis C (HCV). It was founded in 2006 and is based in San Jose, California.
Intarcia Therapeutics is a biotech company that focuses on the development of biologics and peptides for the treatment of cardio-renal-metabolic diseases. The company's main offerings include a pipeline of long-acting GLP-1 receptor agonists and other peptide-based therapies designed to improve the management of chronic diseases. Intarcia primarily serves sectors in the healthcare industry that are involved with chronic disease management and biopharmaceuticals. It was founded in 1995 and is based in Boston, Massachusetts.
Corimmun focuses on the development of therapeutics for the treatment of congestive heart failure and atherosclerosis. It focuses on personalized medicine for cardiovascular diseases. It was founded in 2006 and is based in Martinsried, Germany.
Intercept Pharmaceuticals develops therapeutics for liver diseases, specifically targeting conditions like severe alcohol-associated hepatitis and primary biliary cholangitis through Farnesoid X Receptor (FXR) biology. It was founded in 2002 and is based in Morristown, New Jersey.
Marval Biosciences is an early stage company, developing contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Marval's lead candidate, NCTX, targets cardiovascular imaging.
Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.
Loading...